Adaptimmune Ltd. Selects SCiAN Services' EDC(PRO) Solution to Support a Series of Clinical Trials Starting in 2013
2/12/2013 9:06:57 AM
More...
|
NeoStem, Inc.'s Subsidiary, Progenitor Cell Therapy, Enters Into a Cell Therapy Manufacturing Services Agreement With Adaptimmune Ltd.
1/16/2013 9:18:02 AM
More...
|
Adaptimmune Ltd. Announces Exclusive License With Life Technologies (LIFE) on Proprietary Manufacturing Process for T Cell Therapy Using Its Modified T Cell Receptors
1/7/2013 12:54:16 PM
More...
|
Adaptimmune Ltd. Announces Preliminary Results From an Early Phase Trial of Gene Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma
12/13/2012 10:12:39 AM
More...
|
Adaptimmune Ltd. Announces Preliminary Results From an Early Phase Trial of Gene Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma
12/11/2012 11:18:58 AM
More...
|
Investigators to Present Preliminary Findings for Adaptimmune Ltd.'s Gene Engineered T Cells in Myeloma at the Annual American Society of Hematology Meeting on Monday 10 December
11/16/2012 11:27:23 AM
More...
|
Adaptimmune Ltd. Announces New Board Appointments as Clinical Programmes Get Underway
9/19/2011 10:41:09 AM
More...
|
Adaptimmune Ltd. Announces Opening of Pilot Clinical Trial in Synovial Sarcoma
7/25/2011 10:01:16 AM
More...
|
Adaptimmune Ltd. Announces Opening of Phase I/II Clinical Trial for Metastatic Melanoma
6/13/2011 10:04:21 AM
More...
|